Human CD117 / c-kit Protein, Fc Tag (MALS verified)

Protein

RT

50.2 kDa

c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.

CD117

This protein carries a human IgG1 Fc tag at the C-terminus. The protein has a calculated MW of 50.2 kDa. The protein migrates as 65-90 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

PBS, pH7.4

trehalose